{"id": "article-22235_0", "title": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity", "content": "Gestational trophoblastic disease (GTD) involves both benign and malignant entities that include hydatidiform mole (complete and partial), choriocarcinoma, invasive mole, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT). The latter four, known as gestational trophoblastic neoplasia (GTN), can metastasize and be fatal if not treated. This activity reviews the etiology and pathophysiology of GTN in the clinical setting. Participants will gain insights into evidence-based diagnostic approaches, including histopathological evaluation and imaging modalities, to facilitate accurate and timely diagnosis.\u00a0Clinicians will delve into the multidisciplinary management of GTN, including surgical techniques, chemotherapy regimens, and emerging targeted therapies.", "contents": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity. Gestational trophoblastic disease (GTD) involves both benign and malignant entities that include hydatidiform mole (complete and partial), choriocarcinoma, invasive mole, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT). The latter four, known as gestational trophoblastic neoplasia (GTN), can metastasize and be fatal if not treated. This activity reviews the etiology and pathophysiology of GTN in the clinical setting. Participants will gain insights into evidence-based diagnostic approaches, including histopathological evaluation and imaging modalities, to facilitate accurate and timely diagnosis.\u00a0Clinicians will delve into the multidisciplinary management of GTN, including surgical techniques, chemotherapy regimens, and emerging targeted therapies."}
{"id": "article-22235_1", "title": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity", "content": "The activity\u00a0addresses challenges in treatment, including considerations for fertility preservation, managing complications, and follow-up surveillance. It emphasizes patient-centered care and shared decision-making and highlights the need for effective communication and collaboration among the interprofessional team to achieve optimal, comprehensive care for patients with GTN.", "contents": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity. The activity\u00a0addresses challenges in treatment, including considerations for fertility preservation, managing complications, and follow-up surveillance. It emphasizes patient-centered care and shared decision-making and highlights the need for effective communication and collaboration among the interprofessional team to achieve optimal, comprehensive care for patients with GTN."}
{"id": "article-22235_2", "title": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity", "content": "Objectives: Implement appropriate screening measures, such as evaluating persistent or rising human chorionic gonadotropin levels and identifying clinical signs and symptoms suggestive of gestational trophoblastic neoplasia (GTN). Differentiate the pathophysiology and distinguishing features of various GTN subtypes, including invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Assess the current evidence-based treatment strategies for managing GTN, including surgical interventions, chemotherapy regimens, and targeted therapies. Apply interprofessional team strategies for improving clinical coordination to ensure comprehensive and individualized care for patients with GTN. Access free multiple choice questions on this topic.", "contents": "Gestational Trophoblastic Neoplasia -- Continuing Education Activity. Objectives: Implement appropriate screening measures, such as evaluating persistent or rising human chorionic gonadotropin levels and identifying clinical signs and symptoms suggestive of gestational trophoblastic neoplasia (GTN). Differentiate the pathophysiology and distinguishing features of various GTN subtypes, including invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Assess the current evidence-based treatment strategies for managing GTN, including surgical interventions, chemotherapy regimens, and targeted therapies. Apply interprofessional team strategies for improving clinical coordination to ensure comprehensive and individualized care for patients with GTN. Access free multiple choice questions on this topic."}
{"id": "article-22235_3", "title": "Gestational Trophoblastic Neoplasia -- Introduction", "content": "The first description of gestational trophoblastic disease (GTD) was by Hippocrates around 400 BC. However, it wasn't until 1895\u00a0that Felix Marchand discovered the association\u00a0between pregnancy and GTD:\u00a0when healthy trophoblastic tissue penetrates the endometrium, it creates the placenta, a rich uterine vasculature connecting the fetus and mother; with malignant tissue, invasion is characteristic.", "contents": "Gestational Trophoblastic Neoplasia -- Introduction. The first description of gestational trophoblastic disease (GTD) was by Hippocrates around 400 BC. However, it wasn't until 1895\u00a0that Felix Marchand discovered the association\u00a0between pregnancy and GTD:\u00a0when healthy trophoblastic tissue penetrates the endometrium, it creates the placenta, a rich uterine vasculature connecting the fetus and mother; with malignant tissue, invasion is characteristic."}
{"id": "article-22235_4", "title": "Gestational Trophoblastic Neoplasia -- Introduction", "content": "Although the malignant behavior of a healthy trophoblast is well-controlled, in GTD, the regulatory mechanisms can become dysfunctional, resulting in highly invasive vascular and metastatic tumors. Gestational trophoblastic neoplasia (GTN) involves the malignant entities of GTD, including choriocarcinoma, invasive mole, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Introduction. Although the malignant behavior of a healthy trophoblast is well-controlled, in GTD, the regulatory mechanisms can become dysfunctional, resulting in highly invasive vascular and metastatic tumors. Gestational trophoblastic neoplasia (GTN) involves the malignant entities of GTD, including choriocarcinoma, invasive mole, epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. [1]"}
{"id": "article-22235_5", "title": "Gestational Trophoblastic Neoplasia -- Etiology", "content": "Trophoblasts, the first cells to differentiate from the fertilized ovum,\u00a0supply the embryo with nutrients and eventually form the fetal\u00a0portion of the placenta. These placental trophoblasts are the origin of molar pregnancies and\u00a0GTN and are\u00a0comprised\u00a0of cytotrophoblasts, syncytiotrophoblasts, and intermediate trophoblasts. Specifically, the cytotrophoblasts and syncytiotrophoblasts\u00a0create hydatidiform moles and choriocarcinomas; PSTTs and ETTs arise from intermediate trophoblasts. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Etiology. Trophoblasts, the first cells to differentiate from the fertilized ovum,\u00a0supply the embryo with nutrients and eventually form the fetal\u00a0portion of the placenta. These placental trophoblasts are the origin of molar pregnancies and\u00a0GTN and are\u00a0comprised\u00a0of cytotrophoblasts, syncytiotrophoblasts, and intermediate trophoblasts. Specifically, the cytotrophoblasts and syncytiotrophoblasts\u00a0create hydatidiform moles and choriocarcinomas; PSTTs and ETTs arise from intermediate trophoblasts. [1]"}
{"id": "article-22235_6", "title": "Gestational Trophoblastic Neoplasia -- Epidemiology", "content": "The true incidence of GTN is difficult to definitively quantify, as data concerning the total number of pregnancies and trophoblastic disease vary. Approximately 50% of GTN cases arise\u00a0after a molar pregnancy, whereas 25% may develop after miscarriage, termination, or\u00a0ectopic pregnancy; the remaining 25% may result after a preterm or term pregnancy.", "contents": "Gestational Trophoblastic Neoplasia -- Epidemiology. The true incidence of GTN is difficult to definitively quantify, as data concerning the total number of pregnancies and trophoblastic disease vary. Approximately 50% of GTN cases arise\u00a0after a molar pregnancy, whereas 25% may develop after miscarriage, termination, or\u00a0ectopic pregnancy; the remaining 25% may result after a preterm or term pregnancy."}
{"id": "article-22235_7", "title": "Gestational Trophoblastic Neoplasia -- Epidemiology", "content": "When GTN develops after a molar pregnancy, it is usually an invasive mole\u00a0or choriocarcinoma, rarely a PSTT or an ETT.\u00a0After a complete molar pregnancy, approximately 15% of patients will have persistent local disease with invasion, and 5% may develop metastatic disease. GTN after nonmolar pregnancy occurs in about 2 to 200 per 100,000 pregnancies (depending on global reporting) and is typically a choriocarcinoma. GTN after pregnancy loss occurs in\u00a01 in 15,000 cases;\u00a0GTN after term pregnancy occurs in 1 in 150,000 cases. [2] [3]", "contents": "Gestational Trophoblastic Neoplasia -- Epidemiology. When GTN develops after a molar pregnancy, it is usually an invasive mole\u00a0or choriocarcinoma, rarely a PSTT or an ETT.\u00a0After a complete molar pregnancy, approximately 15% of patients will have persistent local disease with invasion, and 5% may develop metastatic disease. GTN after nonmolar pregnancy occurs in about 2 to 200 per 100,000 pregnancies (depending on global reporting) and is typically a choriocarcinoma. GTN after pregnancy loss occurs in\u00a01 in 15,000 cases;\u00a0GTN after term pregnancy occurs in 1 in 150,000 cases. [2] [3]"}
{"id": "article-22235_8", "title": "Gestational Trophoblastic Neoplasia -- Epidemiology", "content": "Following a molar pregnancy, the risk of a\u00a0repeat mole rises to 1% to 2%. Following\u00a0two molar gestations, the risk of having a third mole is 15% to 20%. The prevalence of choriocarcinomas, PSTTs, and ETTs is unclear, as these diseases can emerge following pregnancy. [1] [4] [5]", "contents": "Gestational Trophoblastic Neoplasia -- Epidemiology. Following a molar pregnancy, the risk of a\u00a0repeat mole rises to 1% to 2%. Following\u00a0two molar gestations, the risk of having a third mole is 15% to 20%. The prevalence of choriocarcinomas, PSTTs, and ETTs is unclear, as these diseases can emerge following pregnancy. [1] [4] [5]"}
{"id": "article-22235_9", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "All types of\u00a0GTN originate from the placenta. Hydatidiform moles (HMs) and choriocarcinomas emerge from villous trophoblasts,\u00a0whereas PSTTs and ETTs arise from intermediate trophoblasts. First-trimester complete\u00a0HMs show aberrant budding, villous structures with trophoblastic hyperplasia, crumpled villous blood vessels, and stromal karyorrhectic debris. In contrast, early partial\u00a0HMs show patchy villous hydrops, dispersed abnormally shaped erratic villi, patchy trophoblastic hyperplasia, and trophoblastic pseudo-inclusions.", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. All types of\u00a0GTN originate from the placenta. Hydatidiform moles (HMs) and choriocarcinomas emerge from villous trophoblasts,\u00a0whereas PSTTs and ETTs arise from intermediate trophoblasts. First-trimester complete\u00a0HMs show aberrant budding, villous structures with trophoblastic hyperplasia, crumpled villous blood vessels, and stromal karyorrhectic debris. In contrast, early partial\u00a0HMs show patchy villous hydrops, dispersed abnormally shaped erratic villi, patchy trophoblastic hyperplasia, and trophoblastic pseudo-inclusions."}
{"id": "article-22235_10", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "Morphological differentiation of nonmolar miscarriage from a partial\u00a0HM can be complicated, as villous dysmorphism can present without the characteristic trophoblastic hyperplasia\u00a0of the partial mole. Furthermore, ploidy analysis\u00a0demonstrated by in situ hybridization or flow cytometry can differentiate diploid from triploid conceptions. Still, it cannot distinguish between a complete mole and a diploid nonmolar miscarriage or molar and nonmolar triploid. In these instances, molecular investigations are necessary.", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. Morphological differentiation of nonmolar miscarriage from a partial\u00a0HM can be complicated, as villous dysmorphism can present without the characteristic trophoblastic hyperplasia\u00a0of the partial mole. Furthermore, ploidy analysis\u00a0demonstrated by in situ hybridization or flow cytometry can differentiate diploid from triploid conceptions. Still, it cannot distinguish between a complete mole and a diploid nonmolar miscarriage or molar and nonmolar triploid. In these instances, molecular investigations are necessary."}
{"id": "article-22235_11", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "Infrequently, a molar pregnancy can coexist with a normal pregnancy. The diagnosis is usually made\u00a0by\u00a0ultrasound. Despite the high risk of spontaneous abortion, 40% to 60% of cases result in live births. The risk of\u00a0GTN in a coexisting molar and normal pregnancy\u00a0is 27% to 46%; in\u00a0a singleton molar pregnancy, the risk is 15% to 20%. Pregnancy can proceed if there are no complications, negative genetic studies,\u00a0and\u00a0normal ultrasound findings. [6]", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. Infrequently, a molar pregnancy can coexist with a normal pregnancy. The diagnosis is usually made\u00a0by\u00a0ultrasound. Despite the high risk of spontaneous abortion, 40% to 60% of cases result in live births. The risk of\u00a0GTN in a coexisting molar and normal pregnancy\u00a0is 27% to 46%; in\u00a0a singleton molar pregnancy, the risk is 15% to 20%. Pregnancy can proceed if there are no complications, negative genetic studies,\u00a0and\u00a0normal ultrasound findings. [6]"}
{"id": "article-22235_12", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "Choriocarcinomas are malignant human chorionic gonadotropin (hCG)-releasing epithelial tumors with central necrosis and a characteristic biphasic structure. Intraplacental choriocarcinomas can also\u00a0occur and\u00a0are\u00a0likely responsible for metastatic disease after term pregnancies. The majority of neonatal choriocarcinomas\u00a0are a result of metastatic spread from intraplacental choriocarcinomas.", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. Choriocarcinomas are malignant human chorionic gonadotropin (hCG)-releasing epithelial tumors with central necrosis and a characteristic biphasic structure. Intraplacental choriocarcinomas can also\u00a0occur and\u00a0are\u00a0likely responsible for metastatic disease after term pregnancies. The majority of neonatal choriocarcinomas\u00a0are a result of metastatic spread from intraplacental choriocarcinomas."}
{"id": "article-22235_13", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "PSTTs are malignant tumors formed from uterine lesions with less hemorrhage, necrosis, and lower hCG concentrations than choriocarcinomas. [1] Human placental lactogen (hPL), expressed by syncytiotrophoblasts, is highly expressed in the trophoblasts of PSTTs. [7]", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. PSTTs are malignant tumors formed from uterine lesions with less hemorrhage, necrosis, and lower hCG concentrations than choriocarcinomas. [1] Human placental lactogen (hPL), expressed by syncytiotrophoblasts, is highly expressed in the trophoblasts of PSTTs. [7]"}
{"id": "article-22235_14", "title": "Gestational Trophoblastic Neoplasia -- Pathophysiology", "content": "ETTs, the rarest of GTN types, demonstrate nests of tumor cells made of fairly uniform mononucleate intermediate trophoblasts. These nests are interspersed between necrotic debris and hyaline degeneration. ETTs may appear as discrete hemorrhagic, solid, or cystic lesions. [8] [9] Extremely\u00a0rare cases of mixed GTN tumors have been reported. Choriocarcinoma may coexist with PSTT and/or ETT. Diagnosis and treatment of these neoplasms is challenging due to limited data. [10]", "contents": "Gestational Trophoblastic Neoplasia -- Pathophysiology. ETTs, the rarest of GTN types, demonstrate nests of tumor cells made of fairly uniform mononucleate intermediate trophoblasts. These nests are interspersed between necrotic debris and hyaline degeneration. ETTs may appear as discrete hemorrhagic, solid, or cystic lesions. [8] [9] Extremely\u00a0rare cases of mixed GTN tumors have been reported. Choriocarcinoma may coexist with PSTT and/or ETT. Diagnosis and treatment of these neoplasms is challenging due to limited data. [10]"}
{"id": "article-22235_15", "title": "Gestational Trophoblastic Neoplasia -- Histopathology", "content": "Histological features of GTN types:", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology. Histological features of GTN types:"}
{"id": "article-22235_16", "title": "Gestational Trophoblastic Neoplasia -- Histopathology -- Complete HM", "content": "Karyotype: 46,XX (majority); 46,XY; no fetus/embryo,\u00a0diffuse swelling of villi, and expanded trophoblastic hyperplasia.", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology -- Complete HM. Karyotype: 46,XX (majority); 46,XY; no fetus/embryo,\u00a0diffuse swelling of villi, and expanded trophoblastic hyperplasia."}
{"id": "article-22235_17", "title": "Gestational Trophoblastic Neoplasia -- Histopathology -- Partial HM", "content": "Karyotype: triploid (69,XXY;\u00a069,XYY;\u00a069,XXX); abnormal fetus/embryo, central swelling of villi, and central trophoblastic hyperplasia.", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology -- Partial HM. Karyotype: triploid (69,XXY;\u00a069,XYY;\u00a069,XXX); abnormal fetus/embryo, central swelling of villi, and central trophoblastic hyperplasia."}
{"id": "article-22235_18", "title": "Gestational Trophoblastic Neoplasia -- Histopathology -- Gestational Choriocarcinoma", "content": "Diffusely penetrative growth involving the endomyometrium. Tumor cells recapitulate chorionic villous trophoblasts of different types and are arranged in biphasic to triphasic growth arrangements. Sheets or cords of mononuclear tumor cells are surrounded by layers of multinuclear syncytiotrophoblasts. Lymphovascular tumor thrombi are usually present.", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology -- Gestational Choriocarcinoma. Diffusely penetrative growth involving the endomyometrium. Tumor cells recapitulate chorionic villous trophoblasts of different types and are arranged in biphasic to triphasic growth arrangements. Sheets or cords of mononuclear tumor cells are surrounded by layers of multinuclear syncytiotrophoblasts. Lymphovascular tumor thrombi are usually present."}
{"id": "article-22235_19", "title": "Gestational Trophoblastic Neoplasia -- Histopathology -- PSTT", "content": "Tumor cells invade the myometrium with vascular/lymphatic invasion. Focal hemorrhage and necrosis are seen in nearly one-half of cases, whereas transmural myometrial invasion is seen in 10% of cases. Perforation\u00a0can\u00a0occur.", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology -- PSTT. Tumor cells invade the myometrium with vascular/lymphatic invasion. Focal hemorrhage and necrosis are seen in nearly one-half of cases, whereas transmural myometrial invasion is seen in 10% of cases. Perforation\u00a0can\u00a0occur."}
{"id": "article-22235_20", "title": "Gestational Trophoblastic Neoplasia -- Histopathology -- ETT", "content": "The tumor usually creates discrete nodules or cystic hemorrhagic masses that deeply invade the surrounding tissues. Hemorrhage, necrosis, ulceration, and fistulas can be seen. Characteristically, ETT demonstrates nodular, expandable growth of uniform, medium-sized tumor cells organized in nests, cords, or large sheets. [11] [12]", "contents": "Gestational Trophoblastic Neoplasia -- Histopathology -- ETT. The tumor usually creates discrete nodules or cystic hemorrhagic masses that deeply invade the surrounding tissues. Hemorrhage, necrosis, ulceration, and fistulas can be seen. Characteristically, ETT demonstrates nodular, expandable growth of uniform, medium-sized tumor cells organized in nests, cords, or large sheets. [11] [12]"}
{"id": "article-22235_21", "title": "Gestational Trophoblastic Neoplasia -- History and Physical", "content": "Due to the routine use of ultrasonography and quantitative beta-hCG testing, patients with complete\u00a0HMs are commonly diagnosed early in gestation.\u00a0Common clinical presentations include vaginal bleeding, usually taking place at 6\u00a0to 16 gestational weeks (46% of cases), large-for-dates uterine size (24% of cases), and hyperemesis (14% of cases). Patients\u00a0may also be asymptomatic at the time of diagnosis. [13]", "contents": "Gestational Trophoblastic Neoplasia -- History and Physical. Due to the routine use of ultrasonography and quantitative beta-hCG testing, patients with complete\u00a0HMs are commonly diagnosed early in gestation.\u00a0Common clinical presentations include vaginal bleeding, usually taking place at 6\u00a0to 16 gestational weeks (46% of cases), large-for-dates uterine size (24% of cases), and hyperemesis (14% of cases). Patients\u00a0may also be asymptomatic at the time of diagnosis. [13]"}
{"id": "article-22235_22", "title": "Gestational Trophoblastic Neoplasia -- History and Physical", "content": "Patients with partial\u00a0HMs are typically not diagnosed before surgical uterine evacuation. Histological examination of curettage specimens after incomplete or missed abortion is required for the diagnosis. As with complete HMs, most patients with partial\u00a0HMs (75%) report vaginal bleeding, and they generally present later than those with complete HMs. Complete HMs are typically associated with a considerably elevated hCG level. Nearly one-half of patients with complete HMs have pre-evacuation hCG levels greater than 100,000 mIU/mL. Such elevated levels\u00a0occur in less than 10% of patients with partial HM. [1]", "contents": "Gestational Trophoblastic Neoplasia -- History and Physical. Patients with partial\u00a0HMs are typically not diagnosed before surgical uterine evacuation. Histological examination of curettage specimens after incomplete or missed abortion is required for the diagnosis. As with complete HMs, most patients with partial\u00a0HMs (75%) report vaginal bleeding, and they generally present later than those with complete HMs. Complete HMs are typically associated with a considerably elevated hCG level. Nearly one-half of patients with complete HMs have pre-evacuation hCG levels greater than 100,000 mIU/mL. Such elevated levels\u00a0occur in less than 10% of patients with partial HM. [1]"}
{"id": "article-22235_23", "title": "Gestational Trophoblastic Neoplasia -- Evaluation", "content": "Ultrasound is the primary diagnostic tool for GTN. [14] Ultrasound of a complete mole characteristically shows a uterus filled with a heterogeneous mass (called the \"snowstorm\" sign), with the absence of fetal development and the presence of theca lutein ovarian cysts. Unfortunately, these findings are not\u00a0detectable in the first trimester.", "contents": "Gestational Trophoblastic Neoplasia -- Evaluation. Ultrasound is the primary diagnostic tool for GTN. [14] Ultrasound of a complete mole characteristically shows a uterus filled with a heterogeneous mass (called the \"snowstorm\" sign), with the absence of fetal development and the presence of theca lutein ovarian cysts. Unfortunately, these findings are not\u00a0detectable in the first trimester."}
{"id": "article-22235_24", "title": "Gestational Trophoblastic Neoplasia -- Evaluation", "content": "Due to high false-negative and false-positive rates with ultrasound, specifically in the case of partial HMs, histological examination is necessary to reach the final diagnosis. As histological examination may not be\u00a0practical after every termination, testing the hCG level\u00a03 to\u00a04 weeks posttermination to verify a negative result\u00a0is highly recommended. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Evaluation. Due to high false-negative and false-positive rates with ultrasound, specifically in the case of partial HMs, histological examination is necessary to reach the final diagnosis. As histological examination may not be\u00a0practical after every termination, testing the hCG level\u00a03 to\u00a04 weeks posttermination to verify a negative result\u00a0is highly recommended. [1]"}
{"id": "article-22235_25", "title": "Gestational Trophoblastic Neoplasia -- Evaluation", "content": "Patients with postmolar GTN often\u00a0present without\u00a0symptoms or characteristic ultrasound findings; therefore,\u00a0a correlation\u00a0between\u00a0hCG levels and tumor burden is necessary to reach the diagnosis. MRI is\u00a0typically unnecessary in the routine evaluation of GTN, except in cases with atypical presentations, recurrence, ETT, or PSTT. [14]", "contents": "Gestational Trophoblastic Neoplasia -- Evaluation. Patients with postmolar GTN often\u00a0present without\u00a0symptoms or characteristic ultrasound findings; therefore,\u00a0a correlation\u00a0between\u00a0hCG levels and tumor burden is necessary to reach the diagnosis. MRI is\u00a0typically unnecessary in the routine evaluation of GTN, except in cases with atypical presentations, recurrence, ETT, or PSTT. [14]"}
{"id": "article-22235_26", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management", "content": "Different treatment modalities are available for\u00a0GTN, depending on the type and stage.", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management. Different treatment modalities are available for\u00a0GTN, depending on the type and stage."}
{"id": "article-22235_27", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Standard\u00a0Treatments", "content": "These include dilation and curettage (D&C), chemotherapy, hysterectomy, or a combination of these modalities. [15]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Standard\u00a0Treatments. These include dilation and curettage (D&C), chemotherapy, hysterectomy, or a combination of these modalities. [15]"}
{"id": "article-22235_28", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- D&C", "content": "More commonly\u00a0performed\u00a0in molar pregnancy where fertility is desired, monitoring after D&C is essential to ensure no disease recurrence.", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- D&C. More commonly\u00a0performed\u00a0in molar pregnancy where fertility is desired, monitoring after D&C is essential to ensure no disease recurrence."}
{"id": "article-22235_29", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Chemotherapy", "content": "Certain\u00a0types of GTN can be treated by single or combination chemotherapy. Some chemotherapeutic agents used include methotrexate, etoposide, actinomycin D, cyclophosphamide, cisplatin, and vincristine.", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Chemotherapy. Certain\u00a0types of GTN can be treated by single or combination chemotherapy. Some chemotherapeutic agents used include methotrexate, etoposide, actinomycin D, cyclophosphamide, cisplatin, and vincristine."}
{"id": "article-22235_30", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Hysterectomy", "content": "A hysterectomy is the most common treatment option in cases of chemoresistance, severe disease,\u00a0or lack of desire\u00a0for future fertility. [16]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Hysterectomy. A hysterectomy is the most common treatment option in cases of chemoresistance, severe disease,\u00a0or lack of desire\u00a0for future fertility. [16]"}
{"id": "article-22235_31", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Hysterectomy", "content": "Initial management of nonmetastatic PSTT or ETT is hysterectomy and salpingectomy, with or without lymph node sampling. In metastatic PSTT or ETT cases, if feasible, hysterectomy,\u00a0salpingectomy, and resection of metastatic disease are followed by platinum-based chemotherapy. [NCCN Guidelines 2022]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Hysterectomy. Initial management of nonmetastatic PSTT or ETT is hysterectomy and salpingectomy, with or without lymph node sampling. In metastatic PSTT or ETT cases, if feasible, hysterectomy,\u00a0salpingectomy, and resection of metastatic disease are followed by platinum-based chemotherapy. [NCCN Guidelines 2022]"}
{"id": "article-22235_32", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Prophylactic chemotherapy", "content": "Prophylactic chemotherapy has been proposed in\u00a0place of monitoring hCG levels until disease clearance criteria are met.\u00a0The\u00a0treatment has been reported to\u00a0decrease intense chemotherapy regimens and boost the chance of complete healing. [16] [17] However, a recent Cochrane Review discourages this practice. [17]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Prophylactic chemotherapy. Prophylactic chemotherapy has been proposed in\u00a0place of monitoring hCG levels until disease clearance criteria are met.\u00a0The\u00a0treatment has been reported to\u00a0decrease intense chemotherapy regimens and boost the chance of complete healing. [16] [17] However, a recent Cochrane Review discourages this practice. [17]"}
{"id": "article-22235_33", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Second D&C", "content": "A\u00a0second D&C\u00a0may be performed after\u00a0a molar pregnancy evacuation if the hCG level remains nonreassuring. However, if there is a high risk of uterine perforation or hemorrhage, a second D&C must not be performed. [16] A prospective, multicenter study was conducted in Canada in 2016 to evaluate the efficacy and safety of this procedure in 64 patients with low-risk, nonmetastatic GTN, using the World Health Organization (WHO)\u00a0prognostic score. The study concluded that a second D&C cured 40% of the patients without complications when used as an initial treatment for low-risk, nonmetastatic GTN. [18]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Second D&C. A\u00a0second D&C\u00a0may be performed after\u00a0a molar pregnancy evacuation if the hCG level remains nonreassuring. However, if there is a high risk of uterine perforation or hemorrhage, a second D&C must not be performed. [16] A prospective, multicenter study was conducted in Canada in 2016 to evaluate the efficacy and safety of this procedure in 64 patients with low-risk, nonmetastatic GTN, using the World Health Organization (WHO)\u00a0prognostic score. The study concluded that a second D&C cured 40% of the patients without complications when used as an initial treatment for low-risk, nonmetastatic GTN. [18]"}
{"id": "article-22235_34", "title": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Drug-resistant GTN", "content": "Approximately 0.5%\u00a0to 5% of women experience drug-resistant\u00a0GTN and may die. Pembrolizumab\u00a0is one of the drugs studied for use in this situation, and the results show that it represents a valuable new approach for treating drug-resistant GTN. [19] Other more complex regimens have been proposed, yet were found to be associated with additional adverse effects. Future\u00a0randomized controlled trials\u00a0must be conducted to assess alternate regimens and their efficacy. [20]", "contents": "Gestational Trophoblastic Neoplasia -- Treatment / Management -- Drug-resistant GTN. Approximately 0.5%\u00a0to 5% of women experience drug-resistant\u00a0GTN and may die. Pembrolizumab\u00a0is one of the drugs studied for use in this situation, and the results show that it represents a valuable new approach for treating drug-resistant GTN. [19] Other more complex regimens have been proposed, yet were found to be associated with additional adverse effects. Future\u00a0randomized controlled trials\u00a0must be conducted to assess alternate regimens and their efficacy. [20]"}
{"id": "article-22235_35", "title": "Gestational Trophoblastic Neoplasia -- Differential Diagnosis", "content": "The differential diagnosis will largely depend on whether metastasis has occurred and, if so, to which organs. The differential diagnosis\u00a0for GTN includes[21]: Incomplete abortion Ectopic pregnancy Cornual pregnancy Pregnancy in the rudimentary uterine horn hCG-secreting germ-cell tumors Biliary obstruction Bladder cancer", "contents": "Gestational Trophoblastic Neoplasia -- Differential Diagnosis. The differential diagnosis will largely depend on whether metastasis has occurred and, if so, to which organs. The differential diagnosis\u00a0for GTN includes[21]: Incomplete abortion Ectopic pregnancy Cornual pregnancy Pregnancy in the rudimentary uterine horn hCG-secreting germ-cell tumors Biliary obstruction Bladder cancer"}
{"id": "article-22235_36", "title": "Gestational Trophoblastic Neoplasia -- Medical Oncology", "content": "In patients with postmolar GTN, evaluation involves a detailed history, physical exam including a pelvic exam, pelvic ultrasound, and imaging including a chest x-ray\u00a0and/or chest, abdominal, and pelvic computed\u00a0tomography (CT) scans. If no extrauterine disease is present, single-agent therapy is appropriate. With\u00a0extrauterine disease, the Federation of Gynecology and Obstetrics (FIGO) stage and prognostic score should be determined to\u00a0assess if the patient is at a low or high risk for persistent or recurrent disease. Studies have reported a 2.9% recurrence rate in patients with nonmetastatic disease and up to a 9.1% recurrence rate in patients with metastatic disease. [21] Single-agent therapy for nonmetastatic disease is generally methotrexate or dactinomycin.", "contents": "Gestational Trophoblastic Neoplasia -- Medical Oncology. In patients with postmolar GTN, evaluation involves a detailed history, physical exam including a pelvic exam, pelvic ultrasound, and imaging including a chest x-ray\u00a0and/or chest, abdominal, and pelvic computed\u00a0tomography (CT) scans. If no extrauterine disease is present, single-agent therapy is appropriate. With\u00a0extrauterine disease, the Federation of Gynecology and Obstetrics (FIGO) stage and prognostic score should be determined to\u00a0assess if the patient is at a low or high risk for persistent or recurrent disease. Studies have reported a 2.9% recurrence rate in patients with nonmetastatic disease and up to a 9.1% recurrence rate in patients with metastatic disease. [21] Single-agent therapy for nonmetastatic disease is generally methotrexate or dactinomycin."}
{"id": "article-22235_37", "title": "Gestational Trophoblastic Neoplasia -- Medical Oncology", "content": "Scoring for metastatic disease is used to determine treatment. In low-risk metastatic disease (prognostic score <7), single-agent methotrexate or dactinomycin is appropriate. Between 10% and 30% of patients\u00a0with low-risk GTN will develop resistance after single-agent chemotherapy,\u00a0whereas up to 50% of patients with high-risk metastatic disease will develop resistance. Patients who develop resistance to the initial single-agent usually will respond to an alternative single agent, and only 5% to 10% of patients will require\u00a0multiagent therapy. [22] [23] [24] Multiagent chemotherapy is indicated in high-risk metastatic disease (prognostic score \u22657), and guidelines\u00a0recommend etoposide, methotrexate, and\u00a0actinomycin D alternating with cyclophosphamide and vincristine\u00a0(EMA/CO). However, up to 40% of patients with high-risk metastatic GTN may not respond or may have a relapse. There are no evidence-based guidelines for second-line treatment, although platinum-based regimens are generally used. [25]", "contents": "Gestational Trophoblastic Neoplasia -- Medical Oncology. Scoring for metastatic disease is used to determine treatment. In low-risk metastatic disease (prognostic score <7), single-agent methotrexate or dactinomycin is appropriate. Between 10% and 30% of patients\u00a0with low-risk GTN will develop resistance after single-agent chemotherapy,\u00a0whereas up to 50% of patients with high-risk metastatic disease will develop resistance. Patients who develop resistance to the initial single-agent usually will respond to an alternative single agent, and only 5% to 10% of patients will require\u00a0multiagent therapy. [22] [23] [24] Multiagent chemotherapy is indicated in high-risk metastatic disease (prognostic score \u22657), and guidelines\u00a0recommend etoposide, methotrexate, and\u00a0actinomycin D alternating with cyclophosphamide and vincristine\u00a0(EMA/CO). However, up to 40% of patients with high-risk metastatic GTN may not respond or may have a relapse. There are no evidence-based guidelines for second-line treatment, although platinum-based regimens are generally used. [25]"}
{"id": "article-22235_38", "title": "Gestational Trophoblastic Neoplasia -- Staging", "content": "GTN staging is based on tumor location and extent as follows: [26] Stage I disease is confined to the uterus Stage II disease involves direct extension or metastasis to other genital structures Stage III disease is\u00a0identified\u00a0by lung metastasis Stage IV disease includes nonpulmonary distant metastasis There are three primary systems used to stage and score GTD: The Clinical Classification System by the National Institute of Health (NIH) The WHO Prognostic\u00a0Scoring System The FIGO Staging and Risk Factor Scoring System, which was revised and edited in 2000", "contents": "Gestational Trophoblastic Neoplasia -- Staging. GTN staging is based on tumor location and extent as follows: [26] Stage I disease is confined to the uterus Stage II disease involves direct extension or metastasis to other genital structures Stage III disease is\u00a0identified\u00a0by lung metastasis Stage IV disease includes nonpulmonary distant metastasis There are three primary systems used to stage and score GTD: The Clinical Classification System by the National Institute of Health (NIH) The WHO Prognostic\u00a0Scoring System The FIGO Staging and Risk Factor Scoring System, which was revised and edited in 2000"}
{"id": "article-22235_39", "title": "Gestational Trophoblastic Neoplasia -- Staging", "content": "The Clinical Classification System is widely used in the United States.\u00a0This approach\u00a0originated from the analyses of patients with metastatic GTN\u00a0treated at the NIH. The system differentiates patients based on the presence or absence of metastatic disease, as all patients with nonmetastatic disease can be cured with initial single-agent chemotherapy.", "contents": "Gestational Trophoblastic Neoplasia -- Staging. The Clinical Classification System is widely used in the United States.\u00a0This approach\u00a0originated from the analyses of patients with metastatic GTN\u00a0treated at the NIH. The system differentiates patients based on the presence or absence of metastatic disease, as all patients with nonmetastatic disease can be cured with initial single-agent chemotherapy."}
{"id": "article-22235_40", "title": "Gestational Trophoblastic Neoplasia -- Staging", "content": "Patients with metastatic disease are further subdivided according to the presence or absence of factors associated with response to initial single-agent chemotherapy. Patients with no high-risk clinical factors will likely benefit from initial single-agent therapy and are labeled as having good-prognosis metastatic GTD; conversely, patients with a single high-risk clinical factor are labeled as having poor-prognosis metastatic GTD. These patients with poor prognosis are at increased risk of\u00a0failing single-agent chemotherapy and\u00a0dying if treated with single-agent therapy followed by multiagent regimens.", "contents": "Gestational Trophoblastic Neoplasia -- Staging. Patients with metastatic disease are further subdivided according to the presence or absence of factors associated with response to initial single-agent chemotherapy. Patients with no high-risk clinical factors will likely benefit from initial single-agent therapy and are labeled as having good-prognosis metastatic GTD; conversely, patients with a single high-risk clinical factor are labeled as having poor-prognosis metastatic GTD. These patients with poor prognosis are at increased risk of\u00a0failing single-agent chemotherapy and\u00a0dying if treated with single-agent therapy followed by multiagent regimens."}
{"id": "article-22235_41", "title": "Gestational Trophoblastic Neoplasia -- Staging", "content": "The WHO Prognostic Scoring System offers precise information regarding disease prognosis. A 97% correlation of risk categorization was shown between the original WHO (1983) and FIGO 2000 systems. [27] The current FIGO prognostic scoring system was adapted from the WHO classification.\u00a0FIGO prognostic scoring is based on individual risk factors that have been shown to predict GTN resistance to single-agent chemotherapy (see Table. FIGO Prognostic Scoring System). Table. FIGO Prognostic Scoring System [Modified from NCCN guidelines Gestational Trophoblastic disease 2022]", "contents": "Gestational Trophoblastic Neoplasia -- Staging. The WHO Prognostic Scoring System offers precise information regarding disease prognosis. A 97% correlation of risk categorization was shown between the original WHO (1983) and FIGO 2000 systems. [27] The current FIGO prognostic scoring system was adapted from the WHO classification.\u00a0FIGO prognostic scoring is based on individual risk factors that have been shown to predict GTN resistance to single-agent chemotherapy (see Table. FIGO Prognostic Scoring System). Table. FIGO Prognostic Scoring System [Modified from NCCN guidelines Gestational Trophoblastic disease 2022]"}
{"id": "article-22235_42", "title": "Gestational Trophoblastic Neoplasia -- Staging", "content": "The patient\u2019s diagnosis is assigned to a stage group represented by a Roman numeral: I, II, III, and IV. Next, the\u00a0sum of the individual prognostic scores is\u00a0noted after a colon. For example, stage II:4 or stage IV:9. Each patient with GTD will be given a stage and score. For patients with PSTT or ETT, only the stage will be given. A risk factor score is not applicable in these cases. Low-risk GTD has\u00a0a total prognostic score of less than 7. High-risk GTD has\u00a0a total prognostic score of 7 or more. [26] [28] [29]", "contents": "Gestational Trophoblastic Neoplasia -- Staging. The patient\u2019s diagnosis is assigned to a stage group represented by a Roman numeral: I, II, III, and IV. Next, the\u00a0sum of the individual prognostic scores is\u00a0noted after a colon. For example, stage II:4 or stage IV:9. Each patient with GTD will be given a stage and score. For patients with PSTT or ETT, only the stage will be given. A risk factor score is not applicable in these cases. Low-risk GTD has\u00a0a total prognostic score of less than 7. High-risk GTD has\u00a0a total prognostic score of 7 or more. [26] [28] [29]"}
{"id": "article-22235_43", "title": "Gestational Trophoblastic Neoplasia -- Prognosis -- Low-Risk Disease", "content": "About 95% of patients diagnosed with an HM who develop neoplasia have a low risk of persistence. For most patients, single-agent chemotherapy with methotrexate or dactinomycin is the treatment of choice. If first-line therapy fails, usually\u00a0due to resistance, it can easily be followed with second-line or, occasionally, third-line chemotherapy, making the overall survival rate almost 100%. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Prognosis -- Low-Risk Disease. About 95% of patients diagnosed with an HM who develop neoplasia have a low risk of persistence. For most patients, single-agent chemotherapy with methotrexate or dactinomycin is the treatment of choice. If first-line therapy fails, usually\u00a0due to resistance, it can easily be followed with second-line or, occasionally, third-line chemotherapy, making the overall survival rate almost 100%. [1]"}
{"id": "article-22235_44", "title": "Gestational Trophoblastic Neoplasia -- Prognosis -- High-Risk Disease", "content": "Most high-risk GTN patients present with metastases months or years following the causative pregnancy. Signs and symptoms differ according to the disease's location. For example, patients with brain metastases\u00a0may present with headaches, seizures, or hemiparesis. In contrast, patients with lung metastasis can present with shortness of breath, hemoptysis, or pleuritic chest pain. Since menstrual irregularity is not always present, the diagnosis can be missed. Recommended imaging studies\u00a0are whole-body\u00a0CT scans, MRI of the brain and pelvis, and Doppler ultrasonography. If the brain scan\u00a0is negative, a lumbar puncture should be done to assess the ratio of cerebrospinal fluid to serum hCG. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Prognosis -- High-Risk Disease. Most high-risk GTN patients present with metastases months or years following the causative pregnancy. Signs and symptoms differ according to the disease's location. For example, patients with brain metastases\u00a0may present with headaches, seizures, or hemiparesis. In contrast, patients with lung metastasis can present with shortness of breath, hemoptysis, or pleuritic chest pain. Since menstrual irregularity is not always present, the diagnosis can be missed. Recommended imaging studies\u00a0are whole-body\u00a0CT scans, MRI of the brain and pelvis, and Doppler ultrasonography. If the brain scan\u00a0is negative, a lumbar puncture should be done to assess the ratio of cerebrospinal fluid to serum hCG. [1]"}
{"id": "article-22235_45", "title": "Gestational Trophoblastic Neoplasia -- Complications", "content": "Commonly reported complications of a molar pregnancy include hyperemesis, hyperthyroidism, vaginal hemorrhage, anemia, preeclampsia, and respiratory distress. [1] Pulmonary complications\u00a0occur less commonly yet are life-threatening. These complications\u00a0include pulmonary edema, pulmonary embolism, pleural effusion, and trophoblastic embolization. [30]", "contents": "Gestational Trophoblastic Neoplasia -- Complications. Commonly reported complications of a molar pregnancy include hyperemesis, hyperthyroidism, vaginal hemorrhage, anemia, preeclampsia, and respiratory distress. [1] Pulmonary complications\u00a0occur less commonly yet are life-threatening. These complications\u00a0include pulmonary edema, pulmonary embolism, pleural effusion, and trophoblastic embolization. [30]"}
{"id": "article-22235_46", "title": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education", "content": "All patients\u00a0with HMs should\u00a0have hCG surveillance and monitoring. Surveillance protocols differ from one country to another, but the principles are identical. In the United Kingdom, serum and urine hCG levels are measured every\u00a02 weeks until the values reach the negative range, then urine hCG levels are\u00a0checked monthly. Patients who achieve negative hCG values within 56 days of uterine evacuation have a low risk of developing malignant disease and are further monitored monthly for\u00a06 months from the evacuation date.", "contents": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education. All patients\u00a0with HMs should\u00a0have hCG surveillance and monitoring. Surveillance protocols differ from one country to another, but the principles are identical. In the United Kingdom, serum and urine hCG levels are measured every\u00a02 weeks until the values reach the negative range, then urine hCG levels are\u00a0checked monthly. Patients who achieve negative hCG values within 56 days of uterine evacuation have a low risk of developing malignant disease and are further monitored monthly for\u00a06 months from the evacuation date."}
{"id": "article-22235_47", "title": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education", "content": "During the hCG follow-up period, patients are advised to use reliable contraception\u00a0(ideally, a combination of methods).\u00a0Following\u00a0hCG monitoring, serum or urine hCG concentrations should be measured\u00a06 and\u00a010 weeks after every pregnancy to ensure no reactivation of previous molar disease. [1]", "contents": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education. During the hCG follow-up period, patients are advised to use reliable contraception\u00a0(ideally, a combination of methods).\u00a0Following\u00a0hCG monitoring, serum or urine hCG concentrations should be measured\u00a06 and\u00a010 weeks after every pregnancy to ensure no reactivation of previous molar disease. [1]"}
{"id": "article-22235_48", "title": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education", "content": "After evacuation of a\u00a0molar pregnancy, follow-up monitoring is critical to detect trophoblastic sequelae (invasive mole or choriocarcinoma), which occur in nearly 15% to 20% of patients with complete\u00a0HMs and 1% to 5%\u00a0of patients with partial HMs. [12]", "contents": "Gestational Trophoblastic Neoplasia -- Deterrence and Patient Education. After evacuation of a\u00a0molar pregnancy, follow-up monitoring is critical to detect trophoblastic sequelae (invasive mole or choriocarcinoma), which occur in nearly 15% to 20% of patients with complete\u00a0HMs and 1% to 5%\u00a0of patients with partial HMs. [12]"}
{"id": "article-22235_49", "title": "Gestational Trophoblastic Neoplasia -- Enhancing Healthcare Team Outcomes", "content": "Management of GTN requires the collaboration of laboratory personnel,\u00a0ultrasonographers, nurses,\u00a0advanced practice practitioners, radiologists, pathologists, gynecologists, medical oncologists, and gynecologic oncologists.\u00a0Healthcare professionals must work together to schedule and coordinate diagnostic tests, such as hCG measurements, imaging studies, and histopathological evaluations, to accurately diagnose GTN and determine disease staging. Subsequently, the interdisciplinary team develops individualized treatment plans based on the specific subtype and stage of GTN. In certain complex situations, referral to centers for trophoblastic disease may be necessary. Regular communication and collaboration\u00a0are essential to ensure ongoing assessment of patients' treatment responses. Adjustments to treatment plans are made based on multidisciplinary discussions and patients' individual needs, allowing\u00a0for coordinated and shared decision-making. Comprehensive patient education on GTN and the critical hCG follow-up requirements\u00a0are best addressed across medical disciplines.\u00a0By setting interprofessional goals and standards, healthcare professionals can work together effectively to provide comprehensive, patient-centered care for individuals with GTN, optimizing treatment outcomes and improving the overall patient experience. [13] [29]", "contents": "Gestational Trophoblastic Neoplasia -- Enhancing Healthcare Team Outcomes. Management of GTN requires the collaboration of laboratory personnel,\u00a0ultrasonographers, nurses,\u00a0advanced practice practitioners, radiologists, pathologists, gynecologists, medical oncologists, and gynecologic oncologists.\u00a0Healthcare professionals must work together to schedule and coordinate diagnostic tests, such as hCG measurements, imaging studies, and histopathological evaluations, to accurately diagnose GTN and determine disease staging. Subsequently, the interdisciplinary team develops individualized treatment plans based on the specific subtype and stage of GTN. In certain complex situations, referral to centers for trophoblastic disease may be necessary. Regular communication and collaboration\u00a0are essential to ensure ongoing assessment of patients' treatment responses. Adjustments to treatment plans are made based on multidisciplinary discussions and patients' individual needs, allowing\u00a0for coordinated and shared decision-making. Comprehensive patient education on GTN and the critical hCG follow-up requirements\u00a0are best addressed across medical disciplines.\u00a0By setting interprofessional goals and standards, healthcare professionals can work together effectively to provide comprehensive, patient-centered care for individuals with GTN, optimizing treatment outcomes and improving the overall patient experience. [13] [29]"}
{"id": "article-22235_50", "title": "Gestational Trophoblastic Neoplasia -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Gestational Trophoblastic Neoplasia -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}